OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review

Bibliography

• Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994;18(Suppl 4):S265-72
   PubMed Web of Science ®Google Scholar
• Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53
   PubMed Web of Science ®Google Scholar
• Ackermann G, Thomalla S, Ackermann F, et al. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea. J Med Microbiol 2005;54:149-53
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2-18
   PubMed Web of Science ®Google Scholar
• Zaiss NH, Weile J, Ackermann G, et al. A case of Clostridium difficile-associated disease due to the highly virulent clone of Clostridium difficile PCR ribotype 027, March 2007 in Germany. Euro Surveill 2007;12:E071115.1
   Google Scholar
• Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64
   PubMed Web of Science ®Google Scholar
• Larson HE, Borriello SP. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother 1990;34:1348-53
   PubMed Web of Science ®Google Scholar
• Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001;48:741-2
   PubMed Web of Science ®Google Scholar
• Jang SS, Hansen LM, Breher JE, et al. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 1997;25(Suppl 2):S266-7
   PubMed Web of Science ®Google Scholar
• Pelaez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49:1157-9
   PubMed Web of Science ®Google Scholar
• Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34:1-6
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7
   PubMed Web of Science ®Google Scholar
• Rafferty ME, McCormick MI, Bopp LH, et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997;18:342-4
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
   PubMed Web of Science ®Google Scholar
• Louie T, Emery W, Krulicki W, et al. Quantitative C. difficile and anaerobic flora cultures during treatment of C. difficile-associated diarrhea with PAR-101 (OPT-80) [abstract P-1649]. 16th ECCMID, Nice, France; 2006
   Google Scholar
• Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-2
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-902
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-9
   PubMed Web of Science ®Google Scholar
• Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-4
   PubMed Web of Science ®Google Scholar
• Louie T, Emery W, Krulicki W, et al. PAR-101 is selectively effective against Clostridium difficile in-vivo and has minimal effect on the anaerobic fecal flora [abstract LB2-30]. 45th ICAAC, Washington, DC, USA; 2005
   Google Scholar
• Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-11
   PubMed Web of Science ®Google Scholar
• Shangle S, Lee C, Okumu F, et al. Safety and pharmacokinetics of OPT-80 in human volunteers [abstract A-5]. 44th ICAAC, Washington, DC, USA; 2004
   Google Scholar
• Okumu F, Walsh RB, Sears P, Shue Y-K. Safety and pharmacocinetics of OPT-80, a novel antibiotics for treatment of Clostridium difficile associated diarrhea (CDAD) [abstract F-726]. 44th ICAAC, Washington, DC, USA; 2004
   Google Scholar
• Louie T, Miller M, Donskex C, et al. Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD) [abstract LB2-29]. 45th ICAAC, Washington, DC, USA; 2005
   Google Scholar
• Parenti F, Pagani H, Beretta G. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J Antibiot (Tokyo) 1975;28:247-52
   PubMed Web of Science ®Google Scholar
• Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo) 1975;28:253-9
   PubMed Web of Science ®Google Scholar
• Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo) 1987;40:567-74
   PubMed Web of Science ®Google Scholar
• Hochlowski JE, Swanson SJ, Ranfranz LM, et al. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. J Antibiot (Tokyo) 1987;40:575-88
   PubMed Web of Science ®Google Scholar
• Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007;8:168-73
   PubMed Web of Science ®Google Scholar
• Par Pharmaceutical Announces Equity Investment in Optimer Pharmaceuticals, May 3, 2005. Available from: http://www.parpharm.com/media/NR_20050503.jsp [Last accessed 22 February 2008]
   Google Scholar
• Par Pharmaceutical Returns Par-101 Marketing Rights to Optimer Pharmaceuticals, Feb. 27, 2007. Available from: http://www.parpharm.com/media/NR_20070227.jsp [Last accessed 22 February 2008]
   Google Scholar
• Gualtieri M, Villain-Guillot P, Latouche J, et al. Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006;50:401-2
   PubMed Web of Science ®Google Scholar
• Osburne MS, Sonenshein AL. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J Virol 1980;33:945-53
   PubMed Web of Science ®Google Scholar
• Babakhani F, Seddon J, Robert N, et al. Effect of inoculum, pH, and cations on the in vitro activity of OPT-80 vs. Clostridium difficile [abstract D-1648]. 45th ICAAC, Washington, DC, USA; 2005
   Google Scholar
• Babakhani F, Seddon J, Robert N, et al. Narrow spectrum activity and low fecal protein binding of OPT-80 and its major hydrolysis metabolite (OP-1118) [abstract E-2076]. 47th ICAAC, Chicago, IL, USA; 2007
   Google Scholar
• Babakhani F, Robert N, Shangle S, et al. Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80 a new makrocyclic compound, against Clostridium difficile [abstract E-2048]. 44th ICAAC, Washington, DC, USA; 2004
   Google Scholar
• Babakhani F, Shangle S, Robert N, et al. Resistance development, cross-resistance, and synergy studies of OPT-80 [abstract E-2047]. 44th ICAAC, Washington, DC, USA; 2004
   Google Scholar
• Optimer Pharmaceuticals initiates second Phase 3 trial of OPT-80 for CDAD, Jan 1, 2007. Available from: http://www.optimerpharma.com/news.asp?news_story=23&page_num=4 [Last accessed 22 February 2008]
   Google Scholar
• Citron DM, Merriam CV, Tyrrell KL, et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47:2334-8
   PubMed Web of Science ®Google Scholar
• Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004;54:211-6
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003;47:337-41
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7
   PubMed Web of Science ®Google Scholar
• Ackermann G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother 2003;51:743-5
   PubMed Web of Science ®Google Scholar
• Karlowski JP, Laing NM, Alfa M, et al. In vitro antimicrobial activities of OPT-80, rifaximin, tigecycline, and comparators against toxin-positive Clostridium difficile cultured from diarrheal stool specimens [abstract E-2080]. 47th ICAAC, Chicago, IL, USA; 2007
   Google Scholar